Doug Hampton 
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China) Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and … Read more
$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024 Halo-Lido Phase 2b trial completed with topline results anticipated by end of calendar Q2 2023 CRANFORD, N.J., May 12, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: … Read more
ST. LOUIS, May 12, 2023 /PRNewswire/ — Centene Corporation (NYSE: CNC) announced today it will present at the Bernstein 39th Annual Strategic Decisions Conference, to be held Wednesday, May 31-Friday, June 2, 2023, in New York City. Centene will present on Thursday, June 1st at 9:00 a.m. Eastern Time (ET). A simultaneous live audio webcast … Read more
SILVER SPRING, Md., May 12, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated information on medical device shortages on the FDA.gov website to reflect the end of the COVID-19 public health emergency (PHE), including providing answers to questions, … Read more
HOUSTON, May 12, 2023 /PRNewswire/ — Today, FemTec Health, Inc. announced the purchase of its Birchbox assets, effective April 12, 2023, by Retention Brands. Early this year as part of its strategic tightening around core healthcare businesses, FemTec Health engaged a national financial consulting firm to advise and explore possibilities for the sale of some of … Read more
SHANGHAI, May 12, 2023 /PRNewswire/ — LaNova Medicines Ltd. (“LaNova Medicines”) announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D). Under the terms of the licensing agreement, AstraZeneca will be … Read more
Organization recognizes and celebrates efforts of child care providers ARLINGTON, Va., May 12, 2023 /PRNewswire/ — Child Care Aware® of America (CCAoA) today celebrates Provider Appreciation Day® alongside states and communities across the country. Provider Appreciation Day is celebrated the Friday before Mother’s Day every year to recognize child care providers, teachers and other … Read more
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for … Read more
the essential The collective against air pollution of the Toulouse conurbation and several associations were joined for a demonstration, by elected representatives from the left. They are asking for a cap on the number of annual flights at Toulouse Blagnac airport, and a curfew at night. “We don’t want so many planes over our heads … Read more
SILVER SPRING, Md., May 12, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes … Read more